Company Overview of PhaseRx, Inc.
PhaseRx, Inc., an RNAi delivery technology company, develops a polymer-based system that enables the systemic delivery of RNAi-based drugs and other macromolecules as therapeutic products. Its PhaseRx polymer system delivers RNAi molecules into the cytoplasm where they can reach and inhibit the desired target of interest. PhaseRx, Inc. was incorporated in 2006 and is based in Seattle, Washington.
410 West Harrison Street
Seattle, WA 98119
Founded in 2006
Key Executives for PhaseRx, Inc.
Compensation as of Fiscal Year 2014.
PhaseRx, Inc. Key Developments
PhaseRx, Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-11-2015 01:40 PM
Dec 3 14
PhaseRx, Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-11-2015 01:40 PM. Venue: Four Seasons Hotel, 757 Market St, San Francisco, CA 94103. Speakers: Robert W. Overell, Co-Founder, Chief Executive Officer, President and Director.
PhaseRx, Inc. Appoints Michael Houston as Vice President, Therapeutics Development
Jan 10 14
PhaseRx, Inc. announced the appointment of Michael Houston, Ph.D., as its Vice President, Therapeutics Development. Dr. Houston brings more than two decades of experience in the manufacturing and development of peptide and oligonucleotide-based therapeutics to PhaseRx. He has directed numerous programs ranging from research to GMP manufacture of clinical trials materials, including nanoparticle-based delivery vehicles for siRNAs. In this new position, Dr. Houston will lead PhaseRx's therapeutics program, which focuses on the advancement of its SMARTT Polymer Technology(R) mRNA nanoparticles. Dr. Houston joins PhaseRx from Marina Biotech where he served as Vice President, Chemistry and Formulations and focused on the development of siRNAS and single stranded oligonucleotides. He has also served at Ascent Therapeutics as Vice President, Preclinical Chemistry and CMC; at MDRNA, Inc. as Vice President, Chemistry & Formulations; and at Nastech Pharmaceuticals as Senior Director, Chemistry and Formulations.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries